Travere Therapeutics, Inc. TVTX) on Monday reported a loss of $37.1 million in its first quarter. The San Diego-based company said it had a loss of 40 cents per share.
Thank you, Nivi. The second quarter of 2025 was a standout for Travere, a reflection of strong strategic execution and continued momentum in delivering against our mission. At the heart of this ...
Investor's Business Daily on MSN
Why this biotech ETF — the IBD stock of the day — just reentered its buy zone
The SPDR S&P Biotech ETF, often referred to simply as the XBI, is Monday's IBD Stock Of The Day. Shares just reentered a buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results